Screened 2026-09-09 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
ResMed holds its Distribution at $219.95. Consolidating, no directional conviction, held for 271 days.
As held on the ledger · 2026-09-09
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 271 days
Price at the screen
$219.95
Valuation
21.09 trailing · 16.64 forward price to earnings
Values screen
PASS· score 89.3
Beta
0.77
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.42%
Below 33%
Interest-bearing debt is just 10.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
26.29%
Below 49%
Money owed to the company is 26.3% of assets, under the 49% limit.
Pass
Revenue purity
0.08%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades at roughly a 20% discount to our $262.88 fair value, strong competitive moat, 8.60% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. A 19.5% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits +7% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Sleep Apnea Leader Trades Past Its Worth
Think of the millions who clip on a ResMed mask each night to breathe easy. The business behind those devices boasts a strong moat, 27 percent profit margins, 25 percent return on equity and steady 11 percent revenue growth. Yet the shares sit at a forward multiple of 16.6 times earnings with our fair value sitting above the current price, leaving no margin of safety.
We pass because the valuation already prices in most of the good news. Fifteen analysts carry a buy rating and a 234 dollar median target, but that optimism leaves little room for disappointment in growth or margins. Ethical screens clear without issue, yet the numbers still mark the stock as overvalued.
The main risk is simple. Any slowdown in sleep-disordered breathing demand or fresh competition on cloud software could compress multiples quickly. Peak earnings at a modest multiple is no bargain when growth moderates.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RMD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (15 analysts) rates it buy, with a mean price target of $271.
2026-08-11Markup · changed$224.03+14.3%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (15 analysts) rates it buy, with a mean price target of $271.
2026-07-18Distribution$196.04+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (15 analysts) rates it buy, with a mean price target of $271.
2026-07-03Distribution$196.04+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$196.04Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
